Category: Cardiovascular Disease
HFpEF Management Update: SGLT2 InhibitorsDecember 12, 2022
New data presented at the European Society of Cardiology Congress in August in Barcelona, went far to strengthen the case for using SGLT2 inhibitors in patients with HFmrEF or HFpEF.
AHA 2022: SPORT Trial Shows OTC Supplements Don’t Beat Statins for Cholesterol-LoweringNovember 22, 2022
Researchers tested 6 widely used dietary supplements often promoted for improving heart health against low-dose statins and placebo.
AHA 2022: Trials of New Agents for Resistant HypertensionNovember 10, 2022
New data presented at the American Heart Association 2022 Scientific Session included 3 trials looking at new drug treatments for resistant hypertension.
Focus on K2P Faculty: Dr. Nishant VermaSeptember 21, 2022
Nishant Verma, MD, MPH, is the section editor for CurrentMD Cardiology’s Arrhythmia and EP track. He is an Associate Professor of Medicine at Northwestern University and serves as the Clinical Cardiology Electrophysiology Fellowship Director and the Director of the EP Lab at Northwestern Medicine Lake Forest Hospital. His clinical practice focuses on all aspects of
ACC/AHA Issue Report for CV and Non-CV Complications of COVID-19June 30, 2022
The American College of Cardiology/American Heart Association Task Force on Clinical Data Standards published a report June 23 listing and defining key data elements related to cardiovascular and noncardiovascular complications of COVID-19.
ACC 2022: Update on Mavacamten for Obstructive Hypertrophic CardiomyopathyApril 29, 2022
Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.
ACC 2022: Novel Gene-Silencing Therapy Cuts Lp(a) by 98%April 11, 2022
Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk.
FDA Approves Empagliflozin for HFpEFMarch 3, 2022
FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.
Rethinking Rhythm Control in AF: Sooner Rather than Later?September 8, 2020
One of the several noteworthy trials presented at the virtual ESC Congress was the EAST-AFNET 4NET 4 trial, which was published concurrently in the New England Journal of Medicine.
News from the 2020 Virtual ESC Congress: EXPLORER-HCMAugust 31, 2020
Lacopo Olivotto, MD, presented the results of the EXPLORER-HCM trial, which examined mavacamten as an alternative to surgical or catheter-based interventions to treat obstructive hypertrophic cardiomyopathy (HCM).